TerminatedNCT05051449
Ketamine for OUD and Comorbid Depression (OUDCD)
Medication studyAges 18–65United States
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- BaltimoreSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 4, 2022
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 5
- Sponsor
- University of Maryland, Baltimore
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05051449
- Official title
Show the full official title
Increasing Retention in Methadone Maintenance Treatment: Feasibility and Preliminary Efficacy of Ketamine for the Treatment of Patients With OUD and Comorbid Depression (OUDCD)
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Baltimore
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Maryland, Baltimore, a university.
Does this study involve medication?
Yes. The study involves medication, including Ketamine Hydrochloride.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as terminated.
